Cost Considerations in Adopting Artificial Intelligence—Societal, Health System and Patient Perspectives
Room RO5
Level 2, Ernest N. Morial Convention Center
Q&A with Paolo S. Silva, MD
Associate Professor of Ophthalmology,
Beetham Eye Institute, Joslin Diabetes Center, Harvard Medical School
What is your presentation about?
Essential to the broader adoption of artificial intelligence approaches are measures to assess its cost effectiveness as it pertains to diabetic retinopathy screening initiatives. This presentation will discuss cost effectiveness analysis (CEA) of AI in diabetic retinopathy screening programs in various settings. Examples in both low and high resource settings will be discussed.
What makes this topic important in 2022?
The application of artificial intelligence (AI) approaches for diabetic retinopathy screening present significant opportunities for advancement. Point of care AI in diabetic retinopathy screening programs have the potential to substantially improve outcomes from the societal, health system and patient perspectives.
How did you become involved with this area of diabetes research or care?
My work is focused on innovative and investigative work in a field that is at the intersection of clinical care and technology with the hope of providing an ideal model for the delivery of evidence-based, highly effective, and efficient diabetes eye care to the population that needs it the most. My primary expertise lies in the fields of ocular telehealth for diabetic retinopathy, ultrawide field (UWF) retinal imaging and electronic medical record review.
[sub-post-content]